Moderna Stock Surges on Positive Cancer Vaccine Trial Results

Font: Financial Modeling Prep  • Aug 19, 2026

Moderna (NASDAQ: MRNA) Surges on Positive Cancer Vaccine Trial Results

• Moderna (NASDAQ: MRNA)'s personalized mRNA cancer vaccine, developed with Merck, showed significant efficacy in a Phase 3 trial for melanoma.
• The positive clinical trial results led to a 147.46% single-day stock surge and analyst upgrades from firms like William Blair.
• Goldman Sachs raised its price target for Moderna to $120.00 from $67.00, reflecting increased confidence in the biotechnology firm's future.

Moderna (NASDAQ: MRNA) is a leading biotechnology company known for its innovative messenger RNA (mRNA) technology, which was central to its widely used COVID-19 vaccine. The company is now working to apply its advanced mRNA platform to other diseases. It is actively developing new treatments, including personalized cancer vaccines in partnership with pharmaceutical giant Merck.

On August 19, 2026, the prominent analyst firm Goldman Sachs maintained its Neutral rating on Moderna. A Neutral rating suggests investors should hold existing positions rather than buy or sell. The firm significantly raised its price target, a projection of a stock's future price, to $120.00 from $67.00. This update came when the biotechnology stock was trading at $153.18.

The stock's high price is driven by major clinical news. Moderna shares surged 147.46% in a single day after the company announced positive results from its Phase 3 cancer vaccine trial. The stock price reached a new 52-week high of $163.47 during the day, with a trading volume of over 159.09 million shares.

The successful trial, called INTerpath-001, involved a personalized mRNA therapy combined with Merck's drug, Keytruda. As highlighted by Zacks Investment Research, the study showed this combination significantly extended the time before melanoma, a serious skin cancer, returned in patients. The trial included over 1,100 patients with high-risk melanoma.

Following the news, another firm, William Blair, upgraded its investment rating on Moderna from Market Perform to Outperform. The stock's dramatic rise also caused record one-day losses for short-sellers, who are investors betting that a stock's price will fall, as reported by Reuters. This shows a strong positive market reaction to the trial data.